33
Participants
Start Date
June 30, 2005
Primary Completion Date
April 30, 2008
Study Completion Date
August 5, 2013
lenalidomide
"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
melphalan
"Phase I - dose escalating: 5mg/m\^2 dose level -1, 5 mg/m\^2 dose level 0, 8 mg/m\^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m\^2 orally days 1-4 every 28 days until progression"
prednisone
60mg/m\^2, orally days 1-4 every 28 days until progression
Mayo Clinic in Florida, Jacksonville
Mayo Clinic, Rochester
Mayo Clinic in Arizona, Scottsdale
Lead Sponsor
National Cancer Institute (NCI)
NIH
Mayo Clinic
OTHER